RxDoctor Payments Data

Katherine Donnithorne, MD

Ophthalmology · Montgomery, ALNPI 1659650778

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,027 of the $6,740 with a category attached, or 74.6%. Carl Zeiss Meditec Digital Innovations LLC accounts for 74.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $5,067 and has fallen 92.2% since, to $394 in 2025.

$6,740in general payments, 2019–2025

Across 74 payments — averaging $91.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec Digital Innovations LLC$5K
  • AbbVie$866
  • Alcon$185
  • Kala Pharmaceuticals, Inc.$144
  • Ivantis, Inc$120
  • Rxsight Inc$90
  • plus $307 from 11 others

What the payments were for

  • Food & beverage$1,69325%
  • Gifts$190%
  • Other$5,02775%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,740 in reported general payments places this provider in the 85th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$21,173
Medicare patients
51
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost23$10,938
Cyclosporine11$8,731
SimbrinzaBrinzolamide/Brimonidine Tart15$3,080
Latanoprost100$1,761
Prednisolone Acetate13$546
Timolol Maleate32$361
MoxifloxacinMoxifloxacin Hcl11$339
ErythromycinErythromycin Base25$282
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$234
Brimonidine Tartrate21$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$866$10,93823 claims
AlconSimbrinza$185$3,08015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →